Company research
Propanc Biopharma, Inc.
CIK 1517681Updated Sep 27, 2026
SecurityPPCB · NASDAQ · equity
Name history
Propanc Health Group Corp · through Apr 5, 2017
PPCB price & chart
Loading TradingView…
NASDAQ:PPCB on TradingView ↗About the company
We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.
In the news
No coverage from other publishers is available.
Financials
FY 2026 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 12,779,912Source | 19,631,808Source | 72,365Source | 60,328Source |
| Property, Plant and Equipment, NetUSD | 3,915Source | 0Source | 0Source | 302Source |
| Current assets: | ||||
| Assets, CurrentUSD | 8,542,590Source | 8,352,816Source | 25,441Source | 19,039Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | 1,406Source | 6,125Source |
| Operating Lease, Right-of-Use AssetUSD | 40,790Source | 59,413Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,378,251Source | 5,725,616Source | 3,851,424Source | 3,177,507Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 3,310Source | 11,612Source | 478,802Source | 6,031Source |
| Additional Paid in CapitalUSD | 152,752,314Source | 138,243,652Source | 61,217,255Source | 60,311,502Source |
| Retained Earnings (Accumulated Deficit)USD | -144,484,230Source | -125,621,520Source | -66,698,220Source | -64,684,732Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,176,255Source | 1,318,917Source | 1,269,581Source | 1,294,876Source |
| Stockholders' Equity Attributable to ParentUSD | 9,401,661Source | 13,906,192Source | -3,779,059Source | -3,117,179Source |
| Liabilities and EquityUSD | 12,779,912Source | 19,631,808Source | 72,365Source | 60,328Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,354,433Source | 5,578,240Source | 3,792,782Source | 3,158,229Source |
| Operating Lease, Liability, CurrentUSD | 24,489Source | — | — | — |
| Accounts Payable, CurrentUSD | 1,131,429Source | 1,249,596Source | 1,213,335Source | 966,718Source |
| Operating Lease, Liability, NoncurrentUSD | 23,818Source | — | — | — |
| Additional Financial Items | ||||
| Long-term DebtUSD | — | 537,921Source | 399,325Source | 390,539Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,498,492Source | 4,621,230Source | — | 2,408Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -183,012Source | 187,732Source | 242,408Source | 80,975Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,682,635Source | -405,168Source | -935,118Source | -1,105,251Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -4,933Source | — | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,933Source | — | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,457,298Source | 490,756Source | 941,894Source | 1,113,719Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 819,918Source | -8,997Source | 11,038Source | 5,980Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 131,687Source | 30,715Source | 9,491Source | 2,883Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance Costs and DiscountsUSD | 19,850Source | 46,200Source | 103,900Source | 79,111Source |
| DepreciationUSD | 997Source | — | 297Source | 1,665Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 13,709Source | 212,450Source | 316,537Source | -530,330Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 32,152Source | -89,243Source | 22,080Source | 5,885Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 32,152Source | -89,243Source | 22,080Source | 5,885Source |
| Gain (Loss) on Extinguishment of DebtUSD | 133,071Source | -871,032Source | 54,565Source | 25,969Source |
| General and Administrative ExpenseUSD | 670,607Source | 57,027,850Source | 1,253,797Source | 1,499,885Source |
| Income Tax Expense (Benefit)USD | — | — | -129,132Source | -129,841Source |
| InterestExpenseNonoperatingUSD | 430,539Source | 563,757Source | 665,841Source | — |
| Net Income (Loss) Attributable to ParentUSD | -18,862,710Source | -58,923,300Source | -1,820,528Source | -2,660,566Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -19,794,956Source | -58,923,300Source | -2,013,488Source | -3,126,839Source |
| Nonoperating Income (Expense)USD | -677,141Source | -1,645,169Source | -413,611Source | -1,013,762Source |
| Operating ExpensesUSD | 18,185,569Source | 57,278,131Source | 1,536,049Source | 1,776,645Source |
| Other Nonoperating Income (Expense)USD | -6,000Source | — | — | — |
| Payments of Financing CostsUSD | — | 264,656Source | — | — |
| Proceeds from Issuance of Common StockUSD | 3,314,458Source | — | 23,057Source | 24,711Source |
| Stock or Unit Option Plan ExpenseUSD | 0Source | — | — | — |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -18,185,569Source | -57,278,131Source | -1,536,049Source | -1,776,645Source |
| Other Nonoperating Income (Expense)USD | -6,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -18,862,710Source | -58,923,300Source | -1,949,660Source | -2,790,407Source |
| Income Tax Expense (Benefit)USD | — | — | -129,132Source | -129,841Source |
| Net Income (Loss) Attributable to ParentUSD | -18,862,710Source | -58,923,300Source | -1,820,528Source | -2,660,566Source |
| Earnings Per Share, BasicUSD per share | -17.62Source | -14.85Source | -0.02Source | -1.8Source |
| Earnings Per Share, DilutedUSD per share | -17.62Source | -14.85Source | -0.02Source | -1.8Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,123,709Source | 3,968,176Source | 85,045,339Source | 1,738,802Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,123,709Source | 3,968,176Source | 85,045,339Source | 1,738,802Source |
| Interest Expense (non-operating)USD | 430,539Source | 563,757Source | 665,841Source | — |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 32,152Source | -89,243Source | 22,080Source | 5,885Source |
| General and Administrative ExpenseUSD | 670,607Source | 57,027,850Source | 1,253,797Source | 1,499,885Source |
| Interest ExpenseUSD | — | — | — | 532,821Source |
| Interest Income, OtherUSD | 161Source | 9Source | 60Source | 36Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -19,794,956Source | -58,923,300Source | -2,013,488Source | -3,126,839Source |
| Nonoperating Income (Expense)USD | -677,141Source | -1,645,169Source | -413,611Source | -1,013,762Source |
| Operating ExpensesUSD | 18,185,569Source | 57,278,131Source | 1,536,049Source | 1,776,645Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 932,246Source | — | 192,960Source | 466,273Source |
| Research and Development ExpenseUSD | 625,477Source | 223,721Source | 248,102Source | 247,919Source |
Offerings
Registration 333-297554
Registration 333-295002
Registration 333-293147
Registration 333-292473
Registration 333-282886
- Gross proceeds
- 4000000.0
- Net proceeds
- 3680000.0
- Deal price
- 4.0
- Shares
- 1000000
- Offering price
- market-price
- Ticker
- PPCB
Filing attachments
ex107.htm · S-1 · 2026-07-17
Calculation of Filing Fee Tables S-1 Propanc Biopharma, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri…
Read attachment ↗ex107.htm · S-1 · 2026-04-10
Calculation of Filing Fee Tables S-1 Propanc Biopharma, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offeri…
Read attachment ↗ex107.htm · S-1 · 2026-02-02
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Propanc Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price (1)(2) F…
Read attachment ↗ex107.htm · S-1 · 2025-12-30
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Propanc Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price (1)(2) F…
Read attachment ↗ex4-1.htm · 8-K · 2025-11-10
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 CERTIFICATE OF DESIGNATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK OF PROPANC BIOPHARMA, INC. I, James Nathanielsz, hereby certify that I am the Chief Executive Officer of Propanc Biopharma, Inc. (the “ Company ”), a corporation organized and existing under the Delaware General Corporation Law (the “ DGCL ”), and further do hereby certify: That pursuant to the authority expressly conferred upon the Board of Directors of the Company (the “…
Read attachment ↗ex4-1.htm · 8-K · 2025-08-19
EX-4.1 3 ex4-1.htm EX-4.1 Exhibit 4.1 Representative’s Warrant THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) D. BORAL CAPITAL LLC, OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF D. BORAL CAPITAL LLC, OR OF ANY SUCH UNDERWRIT…
Read attachment ↗